Bristol Myers Squibb (BMY) stock rallied on Thursday following the release of the global biopharmaceutical company’s Q2 2025 earnings report. It posted adjusted earnings per share of $1.46, which was well above Wall Street’s estimate of $1.07. However, its adjusted EPS was down 29% year-over-year from $2.07.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bristol Myers Squibb reported Q2 revenue of $12.27 billion, another beat compared to analysts’ estimate of $11.38 billion. It also rose 1% year-over-year from $12.2 billion. This came from a 16% increase in Growth Portfolio revenues and a 14% decrease in Legacy Portfolio revenues.
Bristol Myers Squibb stock was up 2.98% in pre-market trading on Thursday, following a 1.88% dip yesterday. The shares have also fallen 15.82% year-to-date and 4.55% over the past 12 months.
Bristol Myers Squibb Guidance
Bristol Myers Squibb provided investors with updated guidance for the full year of 2025 in its latest earnings report. It expects adjusted EPS to range from $6.35 to $6.65, alongside revenue of $46.5 billion to $47.5 billion. Wall Street’s estimates for the year include adjusted EPS of $6.32 and revenue of $46.26 billion. That’s good news for BMY stock, as the company’s outlook is above analysts’ estimates.
Christopher Boerner, Chairman and CEO of Bristol Myers Squibb, said, “In the back half of the year, we’re focused on advancing transformational medicines and delivering on our Growth Portfolio and important pipeline opportunities to shape our growth trajectory.”
Is Bristol Myers Squibb Stock a Buy, Sell, or Hold?
Turning to Wall Street, the analysts’ consensus rating for Bristol Myers Squibb is Hold, based on three Buy, 11 Hold, and a single Sell rating over the past three months. With that comes an average BMY stock price target of $54.18, representing a potential 17.83% upside for the shares. These ratings and price targets are likely to change as analysts update their coverage after today’s earnings report.
